Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 3/17/22 → 3/17/27 |
Funding
- Eli Lilly and Company: $119,143.00
REBUILD-1- I5Q-MC-CGAS(g): A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age with Episodic Migraine # the REBUILD-1 Study
- Qaiser, Sharoon (PI)